4 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow PegBio Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects PB-119, Placebo - Obesity | Phase 1 / Phase 2 | Completed | PegBio Co., Ltd. | 32 | 2024-05-27 | 2025-11-19 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects. PB-718, Placebo - Obesity | Phase 1 / Phase 2 | Completed | PegBio Co., Ltd. | 36 | 2023-07-06 | 2024-04-19 |
| Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes PB-119 100 μg+ Glucophage®, PB-119 150 μg+ Glucophage®, PB-119 200 μg+ Glucophage® - Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Completed | PegBio Co., Ltd. | 214 | 2018-06-13 | 2020-01-22 |
| Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects PB-119 75ug, PB-119 150ug, PB-119 200ug - Type 2 Diabetes Mellitus | Phase 2 | Completed | PegBio Co., Ltd. | 251 | 2018-06-05 | 2020-01-22 |
Diabetes Mellitus, Type 2 (2) · Obesity (2)
Metformin (1)
China (3) · United States (1)
Guoping Yang, Ph D (1) · Linong Ji, MD,PhD (1) · Ping Jin, Ph D (1)